Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-Label, Multicenter, Phase 1/2 Dose-Escalation Study of AME-133v (LY 2469298), Administered Intravenously in Four Weekly Doses, in Subjects With CD20+ Follicular Relapsed or Refractory Non-Hodgkin's Lymphoma

NCT00354926 is registered in ClinicalTrials.gov with Applied Molecular Evolution as lead sponsor.

NCT NCT00354926
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00354926 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-Label, Multicenter, Phase 1/2 Dose-Escalation Study of AME-133v (LY 2469298), Administered Intravenously in Four Weekly Doses, in Subjects With CD20+ Follicular Relapsed or Refractory Non-Hodgkin's Lymphoma
Lead sponsor
Applied Molecular Evolution
Phase
Phase 1
Overall status
Completed
Start date
July 31, 2006
Completion date
January 31, 2009
Enrollment
67 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

non-hodgkin's lymphoma